Guizhou Yibai Pharmaceutical Co (SHSE:600594) Cyclically Adjusted Revenue per Share: ¥4.01 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600594 Guizhou Yibai Pharmaceutical Co Ltd SHSE:600594
54 GF Score
Price ¥3.72
GF Value ¥2.92
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Guizhou Yibai Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Guizhou Yibai Pharmaceutical Co SHSE:600594 -4.12% 54 Cyclically Adjusted Revenue per Share is ¥4.01 as of Jun. 2026. GuruFocus rates SHSE:600594 with a GF Score™ of 54/100 and a GF Value™ of ¥2.92 (Modestly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Guizhou Yibai Pharmaceutical Co's adjusted revenue per share for the three months ended in Jun. 2026 was ¥0.414. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥4.01 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Guizhou Yibai Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -5.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -4.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -2.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Guizhou Yibai Pharmaceutical Co was 13.20% per year. The lowest was -4.40% per year. And the median was 5.55% per year.

As of today (2026-08-23), Guizhou Yibai Pharmaceutical Co's current stock price is ¥3.72. Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ¥4.01. Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 0.93.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Guizhou Yibai Pharmaceutical Co was 5.53. The lowest was 0.65. And the median was 1.21.


Guizhou Yibai Pharmaceutical Co  (SHSE:600594) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.72/4.01
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Guizhou Yibai Pharmaceutical Co was 5.53. The lowest was 0.65. And the median was 1.21.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Guizhou Yibai Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Guizhou Yibai Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guizhou Yibai Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Guizhou Yibai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.72 4.76 4.65 4.37 4.16

Guizhou Yibai Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.26 4.22 4.16 4.12 4.01

SHSE:600594 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guizhou Yibai Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600594
54GF Score
Guizhou Yibai Pharmaceutical Co Ltd SHSE:600594
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guizhou Yibai Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Guizhou Yibai Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.414/116.0564*116.0564
=0.414

Current CPI (Jun. 2026) = 116.0564.

Guizhou Yibai Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.205 102.400 1.366
201612 1.270 102.600 1.437
201703 1.173 103.200 1.319
201706 1.293 103.100 1.455
201709 1.162 104.100 1.295
201712 1.176 104.500 1.306
201803 1.218 105.300 1.342
201806 1.177 104.900 1.302
201809 1.277 106.600 1.390
201812 1.223 106.500 1.333
201903 1.044 107.700 1.125
201906 0.987 107.700 1.064
201909 1.158 109.800 1.224
201912 1.079 111.200 1.126
202003 0.873 112.300 0.902
202006 0.989 110.400 1.040
202009 1.207 111.700 1.254
202012 1.247 111.500 1.298
202103 1.046 112.662 1.078
202106 1.125 111.769 1.168
202109 1.118 112.215 1.156
202112 0.939 113.108 0.963
202203 0.871 114.335 0.884
202206 0.953 114.558 0.965
202209 0.822 115.339 0.827
202212 0.803 115.116 0.810
202303 0.870 115.116 0.877
202306 1.003 114.558 1.016
202309 0.831 115.339 0.836
202312 0.869 114.781 0.879
202403 0.719 115.227 0.724
202406 0.751 114.781 0.759
202409 0.698 115.785 0.700
202412 0.586 114.893 0.592
202503 0.641 115.116 0.646
202506 0.607 114.907 0.613
202509 0.590 115.471 0.593
202512 0.535 115.832 0.536
202603 0.462 116.303 0.461
202606 0.414 116.056 0.414

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥4.01 mean?
Guizhou Yibai Pharmaceutical Co (SHSE:600594) has a Cyclically Adjusted Revenue per Share of ¥4.01 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Guizhou Yibai Pharmaceutical Co and its competitors.
Is Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Guizhou Yibai Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥4.01. Overall, Guizhou Yibai Pharmaceutical Co has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Guizhou Yibai Pharmaceutical Co's Cyclically Adjusted Revenue per Share of ¥4.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Guizhou Yibai Pharmaceutical Co and its competitors. Guizhou Yibai Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥4.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhou Yibai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhou Yibai Pharmaceutical Co (SHSE:600594) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥2.92, compared to a current price of ¥3.72 — trading 27.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥4.01. Guizhou Yibai Pharmaceutical Co's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Guizhou Yibai Pharmaceutical Co (SHSE:600594), the current Cyclically Adjusted Revenue per Share is ¥4.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guizhou Yibai Pharmaceutical Co (SHSE:600594) Overvalued in 2026?

Based on GuruFocus' analysis, Guizhou Yibai Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥3.72 is trading 27.4% above its estimated GF Value™ of ¥2.92. GuruFocus considers Guizhou Yibai Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600594:

  • Cyclically Adjusted Revenue per Share: ¥4.01
  • GF Value™: ¥2.92 vs. price of ¥3.72 (27.4% above fair value)
  • GF Score™: 54/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guizhou Yibai Pharmaceutical Co Business Description

Address No. 220-1 Baiyun Avenue, Guiyang, Guizhou, CHN, 550008
Guizhou Yibai Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical products in China. Its products include tumor, cardio-cerebral vascular, respiratory system, anti-rheumatic, digestive system, pediatric, gynecological, andrological, anti-infection, anti-inflammatory, analgesic, tonic, and other drugs.
54GF Score

Get the complete analysis for SHSE:600594

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥3.72
Price
¥2.92
GF Value